Depressive sleep disorder
Conditions
Interventions
Control group:Dexmedetomidine treatment
Experimental Group 1:0.2mg/kg Esketamine in combination with dexmedetomidine therapy
Experimental Group 2:0.25mg/kg Esketamine in combination with dexmedetomidine therapy
Experimental Group 3:0.3mg/kg Esketamine in combination with dexmedetomidine therapy
Sponsors
Department of Anesthesiology, Changzhou Second People's Hosptial Affiliated to Nanjing Medical University
Eligibility
Sex/Gender
All
Age
16 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Conform to the ' ICD-10 mental and behavioral disorders classification ' F51.0 non-organic insomnia diagnostic criteria ; 2.PSQI score = 16 ; 3.MADRS score 22-35 points ; 4.Patients who did not take any antipsychotics and sedative hypnotic drugs in the past week.
Exclusion criteria
Exclusion criteria: 1.Patients who have previously been diagnosed with bipolar disorder, narcolepsy or sleep apnea, or sleep disorders caused by the psychological effects of other organic diseases such as epilepsy, various chronic diseases, pain, excessive drinking or taking special drugs. 2.Patients with a history of aneurysmal vascular disease, arteriovenous malformation or cerebral hemorrhage. 3.Cardiac conduction dysfunction ; patients with severe heart, liver, lung and kidney dysfunction. 4.Pregnant and lactating women. 5.Patients known to have a history of allergy to the drug in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| deep sleep ratio;light sleep ratio;rapid eye movement ratio;quality of sleep;PSQI sleep score;depression score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum indicators; | — |
Countries
China
Contacts
Public ContactZhouquan Wu
The Second People's Hospital of Changzhou, Jiangsu
Outcome results
None listed